PAVM News and Press, PAVmed Inc. From 03/27/24

2024-03-27 00:53:53 ET More on PAVmed Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details see: PAVmed Non-GAAP EPS of -$1.33 ...

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results PR Newswire Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio tec...

2024-03-26 12:11:19 ET More on PAVmed Seeking Alpha’s Quant Rating on PAVmed Historical earnings data for PAVmed Financial information for PAVmed Read the full article on Seeking Alpha For further details see: PAVmed Q4 2024 Earnings Preview

2024-03-26 09:51:41 ET Major earnings expected before the bell on Wednesday include: Altimmune ( ALT ) Carnival Corporation ( CCL ) Cintas ( CTAS ) Paychex ( PAYX ) Tsakos Energy Navigation ( TNP ) Read the full article on Seeking Alpha ...

Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective VA screening study demonstrates excellent EsoGuard sensitivity of 92.9% and negative ...

PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX PR Newswire The incubator, PMX, and medical device firm Hatch Medical, execute joint venture agreement to complete their development and commercialization, starting with Por...

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference PR Newswire Lucid and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophage...

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 13, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...